The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction
File(s)cc9019.pdf (1.82 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Introduction
The impact of pro-inflammatory cytokines on neuroinflammation and cognitive function after lipopolysaccharide (LPS) challenge remains elusive. Herein we provide evidence that there is a temporal correlation between high-mobility group box 1 (HMGB-1), microglial activation, and cognitive dysfunction. Disabling the interleukin (IL)-1 signaling pathway is sufficient to reduce inflammation and ameliorate the disability.
Methods
Endotoxemia was induced in wild-type and IL-1R-/- mice by intra peritoneal injection of E. Coli LPS (1 mg/kg). Markers of inflammation were assessed both peripherally and centrally, and correlated to behavioral outcome using trace fear conditioning.
Results
Increase in plasma tumor necrosis factor-α (TNFα) peaked at 30 minutes after LPS challenge. Up-regulation of IL-1β, IL-6 and HMGB-1 was more persistent, with detectable levels up to day three. A 15-fold increase in IL-6 and a 6.5-fold increase in IL-1β mRNA at 6 hours post intervention (P < 0.001 respectively) was found in the hippocampus. Reactive microgliosis was observed both at days one and three, and was associated with elevated HMGB-1 and impaired memory retention (P < 0.005). Preemptive administration of IL-1 receptor antagonist (IL-1Ra) significantly reduced plasma cytokines and hippocampal microgliosis and ameliorated cognitive dysfunction without affecting HMGB-1 levels. Similar results were observed in LPS-challenged mice lacking the IL-1 receptor to those seen in LPS-challenged wild type mice treated with IL-1Ra.
Conclusions
These data suggest that by blocking IL-1 signaling, the inflammatory cascade to LPS is attenuated, thereby reducing microglial activation and preventing the behavioral abnormality.
The impact of pro-inflammatory cytokines on neuroinflammation and cognitive function after lipopolysaccharide (LPS) challenge remains elusive. Herein we provide evidence that there is a temporal correlation between high-mobility group box 1 (HMGB-1), microglial activation, and cognitive dysfunction. Disabling the interleukin (IL)-1 signaling pathway is sufficient to reduce inflammation and ameliorate the disability.
Methods
Endotoxemia was induced in wild-type and IL-1R-/- mice by intra peritoneal injection of E. Coli LPS (1 mg/kg). Markers of inflammation were assessed both peripherally and centrally, and correlated to behavioral outcome using trace fear conditioning.
Results
Increase in plasma tumor necrosis factor-α (TNFα) peaked at 30 minutes after LPS challenge. Up-regulation of IL-1β, IL-6 and HMGB-1 was more persistent, with detectable levels up to day three. A 15-fold increase in IL-6 and a 6.5-fold increase in IL-1β mRNA at 6 hours post intervention (P < 0.001 respectively) was found in the hippocampus. Reactive microgliosis was observed both at days one and three, and was associated with elevated HMGB-1 and impaired memory retention (P < 0.005). Preemptive administration of IL-1 receptor antagonist (IL-1Ra) significantly reduced plasma cytokines and hippocampal microgliosis and ameliorated cognitive dysfunction without affecting HMGB-1 levels. Similar results were observed in LPS-challenged mice lacking the IL-1 receptor to those seen in LPS-challenged wild type mice treated with IL-1Ra.
Conclusions
These data suggest that by blocking IL-1 signaling, the inflammatory cascade to LPS is attenuated, thereby reducing microglial activation and preventing the behavioral abnormality.
Date Issued
2010-05-14
Date Acceptance
2010-05-14
Citation
Critical Care (UK), 2010, 14 (3), pp.1-9
ISSN
1364-8535
Publisher
BMC
Start Page
1
End Page
9
Journal / Book Title
Critical Care (UK)
Volume
14
Issue
3
Copyright Statement
© 2010 Terrando et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.,
Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.,
License URL
Identifier
http://ccforum.com/content/14/3/R88
Subjects
Science & Technology
Life Sciences & Biomedicine
Critical Care Medicine
General & Internal Medicine
INTERLEUKIN-1 RECEPTOR ANTAGONIST
BRAIN
ACTIVATION
MEMORY
EXPRESSION
MICROGLIA
EXPOSURE
MEDIATOR
CONTEXT
CELLS
Animals
Cognition Disorders
Cytokines
Endotoxemia
Escherichia coli
HMGB1 Protein
Hippocampus
Interleukin-1
Lipopolysaccharides
Mice
Mice, Inbred C57BL
Microglia
Tumor Necrosis Factor-alpha
Hippocampus
Microglia
Animals
Mice, Inbred C57BL
Mice
Escherichia coli
Endotoxemia
Lipopolysaccharides
Tumor Necrosis Factor-alpha
HMGB1 Protein
Interleukin-1
Cytokines
Cognition Disorders
Emergency & Critical Care Medicine
11 Medical and Health Sciences
Publication Status
Published
Article Number
R88
Date Publish Online
2010-05-14